Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancer, Fallopian Tube”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT05261490
What this trial is testing

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinoma+3 more
Pfizer 10
Very early researchStudy completedNCT01504126
What this trial is testing

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+32 more
M.D. Anderson Cancer Center 32
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Post-approval studies (Phase 4)Ended earlyNCT03164980
What this trial is testing

QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

Who this might be right for
Quality of LifeOvarian CancerRecurrent Ovarian Carcinoma
North Eastern German Society of Gynaecological Oncology 89
Testing effectiveness (Phase 2)WithdrawnNCT01661868
What this trial is testing

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute
Large-scale testing (Phase 3)Study completedNCT00483782
What this trial is testing

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Medical Research Council 1,520
Large-scale testing (Phase 3)Study completedNCT02631876
What this trial is testing

Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Who this might be right for
Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
ImmunoGen, Inc. 366
Early research (Phase 1)Study completedNCT00959582
What this trial is testing

Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC 42
Early research (Phase 1)Ended earlyNCT01243762
What this trial is testing

Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Who this might be right for
Neoplasms Malignant
Merck Sharp & Dohme LLC 47
Testing effectiveness (Phase 2)Looking for participantsNCT05503797
What this trial is testing

Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Who this might be right for
Cancer Harboring BRAF AlterationsHGGLGG+1 more
Fore Biotherapeutics 254
Large-scale testing (Phase 3)Ended earlyNCT01849874
What this trial is testing

MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Low-grade Serous Ovarian CancerLow-grade Serous Fallopian Tube CancerLow-grade Serous Peritoneal Cancer
Pfizer 341
Testing effectiveness (Phase 2)Study completedNCT00032162
What this trial is testing

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Who this might be right for
Cervical CancerEndometrial CancerFallopian Tube Cancer+2 more
AGO Study Group 63
Early research (Phase 1)Study completedNCT01459380
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Who this might be right for
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more
National Cancer Institute (NCI) 41
Testing effectiveness (Phase 2)UnknownNCT04566952
What this trial is testing

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian and Fallopian Tube Cysts and NeoplasmsNeoplasms by Site+16 more
Xiaoxiang Chen 68
Testing effectiveness (Phase 2)Study completedNCT02725489
What this trial is testing

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Who this might be right for
Breast CancerOvarian CancerFallopian Tube Cancer+4 more
Mary Crowley Medical Research Center 13
Early research (Phase 1)Study completedNCT00083213
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Early research (Phase 1)Ended earlyNCT03691376
What this trial is testing

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+9 more
Roswell Park Cancer Institute 4
Testing effectiveness (Phase 2)Study completedNCT02440425
What this trial is testing

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute 42
Not applicableStudy completedNCT01262040
What this trial is testing

Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive

Who this might be right for
Endometrial CancerFallopian Tube CancerOvarian Cancer+5 more
Memorial Sloan Kettering Cancer Center 154
Not applicableStudy completedNCT01544049
What this trial is testing

Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study

Who this might be right for
Ovarian Cancer
University of Washington 24
Next Page